Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.

Autor: Phillips AA; Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA. adp9002@med.cornell.edu.; Division of Hematology and Oncology, Weill Cornell Medical College, 525 East 68th Street Starr Pavilion, 3rd Floor, New York, NY, 10065, USA. adp9002@med.cornell.edu., Harewood JCK; Department of Medicine, New York Presbyterian Queens, Flushing, NY, 11355, USA.
Jazyk: angličtina
Zdroj: Current hematologic malignancy reports [Curr Hematol Malig Rep] 2018 Aug; Vol. 13 (4), pp. 300-307.
DOI: 10.1007/s11899-018-0458-6
Abstrakt: Purpose of Review: ATL is a rare and highly aggressive T cell malignancy caused by HTLV-1. We will review the state of the art of ATL epidemiology, pathogenesis, diagnosis, and treatment.
Recent Findings: Because of population migration, cases of ATL in non-HTLV-1 endemic countries including North America and Europe are increasingly recognized. ATL has diverse clinical manifestations, limited treatment options not widely available globally, and poor prognosis despite therapy. A small subset of patients may achieve prolonged survival with antiviral therapy or allogeneic stem cell transplant. Mogamulizumab, an anti-CCR4 monoclonal antibody, and lenalidomide, an immunomodulatory drug, are approved for ATL in Japan. Molecular studies have identified key alterations in T cell signaling and DNA methylation that may further guide drug development. Patients should be encouraged to enroll in prospective clinical trials when possible. Ongoing, collaborative, international research continues to elucidate disease pathogenesis and contribute to an evolving therapeutic landscape for ATL.
Databáze: MEDLINE
Externí odkaz: